Clinical Trials Browser

Lymphoma, T-Cell, Cutaneous × Brentuximab Vedotin × 1 year × Clear all

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT07178457 2025-09-17

BeCALM

Phase 3 Not yet recruiting

84 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

26 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Clinical Trials

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

BeCALM

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma